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ABSTRACTS A.9 
Population and methods: we analysed 110 episodes of CAP or AECB in 107 pts in our unit from l/Dee/98 to 30/O&99; we 
evaluated antibiotic treatment before and during hospitalization, sputum isolates and serology, mean hospital stay. 
Results: CAP and AECB represented respectively 28% and 61% of the episodes; mean age was 63221~ (16-92y) and 70&9y 
(43-93y) in the 2nd group. Mean hospitalization was 20? 11 d (845d) for CAP and 19+ 12 d (3-75d) for AECB episodes. 71% 
of patients with CAP and 45% of those with AECB had received antibiotic treatment in the 3 days before admission. 43% of 
the patients with CAP received more than one drug; drugs including penicillins (P), cephalosporins (C), fluoroquinolones 
(FQ), macrolides (M). FQ were most frequently used for AECB, followed by C,M,P In 42% of CAP, no germs were isolated 
and in 29% of the cases multiple agents were identified. Similarly no pathogen was identified in 53% of AECB. 
Conclusions: an increased hospital stay in both CAP and AECB episodes was observed compared to mean national values, 
possibly related to patients’ demographics. Relevant differences in ethiology of CAP and AECB were observed compared to 
available reports at other sites, with no recorded case of Pen R S. Pneumoniae. These data further confirm that local 
guidelines and hospital formularies should take into account both clinical and microbiological surveys. 
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Aim: to evaluate efficacy and safety of clarithromycin in the initial treatment of community-acquired pneumonia (CAP) in a 
prospective, noncomparative, multicentre clinical trial. 
Patients and methods: 87 outpatients with symptoms and radiologically confirmed pneumonia were included. We evaluated 
clinical symptoms at the beginning of the treatment, after three days and after the end of the treatment. Chest x-ray and 
laboratory findings including C-reactive protein (CRP) were evaluated at the beginning and not later than 9 days after the end 
of the treatment. Patients received 500 mg of clarithromycin twice daily. 
Results: Duration of treatment was 5 to 14 days (mean 1223 days). Complete radiological resolution was achieved in 72 
patients (85%). Chest pain was present in 67% before and 6% after the treatment, productive cough in 54% vs. 13%, non- 
productive cough in 46% vs. 17%, purulent sputum in 22% vs. O%, muco-purulent sputum in 28% vs. 6%, dyspnea in 54% vs. 
1 l%, chills in 55% vs. l%, pathological physical chest examination in 86% vs. 5%. Mean CRP was 53.0239.9 (SD) mg/l before 
and 11.3? 14.9 (SD) mg/l after the treatment. 97% of patients (84187) were successfully treated (cure or improvement). In 2 
out of 3 failures patients did not complete the treatment due to adverse reactions. 16% (14/87) of all patients experienced 
adverse reactions; most common were transient gastrointestinal symptoms. 
Conclusions: Initial treatment with clarithromycin was highly effective in mild to moderate CAP in adults, and was associated 
with an acceptable incidence of adverse reactions. 
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Objective. The purpose of this study was to determine the effect of age, severity of lung disease, severity and frequency of 
exacerbation, steroid use, choice of an antibiotic and the presence of comorbidity on the outcome of treatment for an acute 
exacerbation of chronic obstructive lung disease (COPD). 
Methods. A retrospective chart analysis was conducted in 107 outpatients with COPD who were treated with an antibiotic for 
an acute exacerbation of COPD over 24 months. Severity of an acute exacerbation was defined using Anthonisen’s criteria of 
increased dyspnea, increased sputum volume and increased sputum purulence. Severity of lung disease was stratified based on 
FEVi% predicted using ATS guidelines (Stage I - FEVl 50%; Stage II - FEVi 35% to 49%; Stage III ~ FEVi ~35%). 
Treatment outcome was judged successful when the patient had no return visit in four weeks for a respiratory problem. Failure 
was defined as a return visit in four weeks for persistent respiratory symptoms that required a change of an antibiotic. 
Results. One-hundred and seven patients with COPD (mean age&SD 66.9k9.5 years) experienced 232 exacerbations over 24 
months. First-line antibiotics (trimethoprim-sulfamethoxazole, ampicillinlamoxicillin and erythromycin) were used to treat 
78% of all exacerbations. Treatment failure was noted in 12.1% of first exacerbations and 14.7% of all exacerbations, with 
more than half the failures requiring hospitalization Host factors that were independently associated with treatment failure 
